Claire Thompson  

Claire is new to the SBC experts panel and is currently working with MRC Technology on their strategy plans. She is very much looking forward to getting involved in the SBC plans for convergence, assisting tenants with product development, positioning and strategy, and running regular PR clinics.

Claire can help SBC companies with:

  • Designing key experiments to show proof-of-concept;
  • Compiling data for regulatory submissions and clinical studies;
  • Writing an impressive business plan;
  • Analysing the competitive landscape;
  • Fine-tuning their product’s competitive advantage;
  • Creating and managing their intellectual property;
  • Producing an impactful company fact sheet/executive summary;
  • Developing compelling investor briefing documents;
  • Developing and rolling out product or company strategy; and
  • Writing and designing powerful promotional materials.
 

Claire is Co-founder and Director at NanoScientium. Here, she enables investors, developers and corporations to fast-track their nanotechnologies into products and profits. She is also Co-founder and Director at Agility Pharma Consulting, providing technical and strategic consulting across the medicines development process.

Claire’s Pharmaceutical Industry experience spans large multi-national, virtual and contract research organisations. Before founding NanoScientium, she was Head of Research and Development with Oxford PharmaScience, an AIM-listed virtual Pharmaceutical company identified as one of the "Top 10 Emerging Technology Companies 2012".

Prior to this, Claire was Associate Director at Molecular Profiles where her role was split between managing a Technical Division and developing and marketing new Client services.

Claire spent 6 years at GSK developing novel molecules and formulations for therapeutic areas such as asthma, cancer, HIV, insomnia, malaria and pain. She attained increasingly senior roles leading global technical teams across R&D and manufacturing to deliver projects to milestones throughout the development lifecycle.

She started her Industrial career at Pfizer developing highly sensitive, novel methods to characterise inhaled and intranasal drugs.

Claire is Chief Scientist of the Academy of Pharmaceutical Sciences. She is Honorary Senior Lecturer in the College of Medical & Dental Sciences at the University of Birmingham. She holds a PhD from School of Pharmacy, University of Nottingham, and a BSc in Biochemistry from the University of St. Andrews.

Funding Partners: